Comparison · NCT05633407-e868a958
Efgartigimod vs Placebo: Number of Participants With ADAs Against Efgartigimod
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Efgartigimod vs Placebo: Number of Participants With ADAs Against Efgartigimod. Trial comparisons, record NCT05633407-e868a958. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05633407-e868a958
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.139 | 0.0608 | 0.287 | wilson | |
| Risk in group 2 | 0.0588 | 0.0105 | 0.27 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0801 | -0.145 | 0.235 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.36 | 0.299 | 18.7 | log | |
| Odds ratio, group 1 over group 2 | 2.58 | 0.277 | 24 | log | |
| Number needed to treat, for one more participant with the outcome on Efgartigimod than on Placebo | 12.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Efgartigimod | Participants received efgartigimod 10 mg/kg via IV infusion once weekly from Day 1 up to 24 weeks. | 5 | 36 | OG000 |
| Group 2 | Placebo | Participants received placebo matched to efgartigimod via IV infusion once weekly from Day 1 up to 24 weeks. | 1 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With ADAs Against Efgartigimod
- Description
Blood samples were collected at specified timepoints to assess anti-drug antibodies (ADAs) against efgartigimod. ADA incidence reported here was defined as total number of participants with treatment-induced and treatment-boosted ADA. Treatment-induced ADA was defined as a baseline negative sample and at least 1 positive post-baseline sample. Treatment-boosted ADA was defined as a baseline positive sample and the titer value increased 4-fold or more compared to baseline.
- Time frame
- Up to Week 24
- Population
- The SAF included all randomized participants who received at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
- NCT number
- NCT05633407
- Phases
- PHASE2
- Conditions
- Postural Orthostatic Tachycardia Syndrome
- Interventions
- Efgartigimod, Placebo
- Lead sponsor
- argenx
- Results first posted
- 2025-05-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05633407?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05633407-e868a958